Skip to main content

Table 1 Demographic and clinicopathological characteristics of 46 patients with gastric cancer

From: Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy

Parameter Number (%)
Age, years  
 >65 14 (30.4%)
 ≤65 32 (69.6%)
Gender  
 Male 36 (78.3%)
 Female 10 (21.7%)
Chemotherapy regimen  
 XELOX 32 (69.6%)
 FOLFOX 14 (30.4%)
Cycles of chemotherapy, median (range) 3 (1–5)
Primary tumor site  
 Upper 1/3 12 (26.1%)
 Middle 1/3 12 (26.1%)
 Low 1/3 22 (47.8%)
Clinical responsea  
 Yes 21 (45.7%)
 No 25 (54.3%)
Clinical benefitb  
 Yes 43 (93.5%)
 No 3 (6.5%)
Types of surgery  
 Total 28 (60.9%)
 Subtotal 18 (39.1%)
Radicality  
 R0 37 (80.4%)
 R1 0
 R2 9 (19.6%)
Combined resection  
 No 45 (97.8%)
 Yes 1 (2.2%)
Differentiation  
 Differentiatedc 15 (32.6%)
 Poorly differentiatedd 31 (67.4%)
Clinical TNM classificatione  
 T stage  
  T3 40 (87%)
  T4 6 (13%)
 N stage  
  N1 14 (30.4%)
  N2 32 (69.6%)
  N3 0
 TNM stage  
  III 40 (87%)
  IV 6 (13%)
Pathological TNM classificatione  
 y T stagef  
  T0 2 (4.3%)
  T1 1 (2.2%)
  T2 6 (13%)
  T3 28 (60.9%)
  T4 9 (19.6%)
 y N stagef  
  N0 8 (17.4%)
  N1 19 (41.3%)
  N2 13 (28.3%)
  N3 6 (13%)
 y TNM stagef  
  Tis 1 (2.2%)
  I 3 (6.5%)
  II 8 (17.4%)
  III 23 (50%)
  IV 11 (23.9%)
  1. CR, complete response, PD, progressive disease; PR, partial response; SD, stable disease; Tis, tumor in situ; TNM, tumor, node metastasis;
  2. aClinical response: Yes means CR and PR; No means SD and PD.
  3. bClinical benefit: Yes means CR and PR and SD; No means PD.
  4. cWell and moderately differentiated adenocarcinoma.
  5. dPoorly differentiated adenocarcinoma, ring cell carcinoma.
  6. eAmerican Joint of Committee On Cancer, sixth edition.
  7. fClassification after neoadjuvant chemotherapy.